Investors
Overview

Investors Overview

Company Profile

Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH.

Recent/Upcoming Events
Jun 05, 2024 at 8:30 AM CEST

Title: Pemvidutide, a glucagon-like peptide 1/glucagon dual receptor agonist, improves metabolic dysfunction-associated steatohepatitis activity and fibrosis in a clinical quantitative systems pharmacology model
(abstract #2881)

Speaker: Sarah Browne, M.D., Vice President, Clinical Development, Altimmune

 

Title: Plasma lipidomic profiling of subjects with overweight or obesity following treatment with the glucagon-like peptide 1/glucagon dual receptor agonist pemvidutide: an investigation of lipid signatures associated with metabolic dysfunction-associated steatohepatitis
(abstract #2985)

Speaker: Scot Roberts, Ph.D., Chief Scientific Officer, Altimmune

 

Title: Pemvidutide treatment is associated with improvement in noninvasive tests indicating greater likelihood of histologic response in subjects with metabolic dysfunction-associated steatotic liver disease: a 24-week, randomized, double-blind, placebo-controlled trial
(abstract #3002)

Speaker: Shaheen Tomah, M.D., Associate Director, Clinical Development, Altimmune

btn Events

 

Investor Contact

Richard Eisenstadt
Chief Financial Officer

Email: reisenstadt@altimmune.com

 

Email Alerts

Automatically receive Altimmune, Inc. financial information by e-mail

Subscribe